Posted by Michael Wonder on 08 Dec 2023
Lilly announces Health Canada's authorisation of Verzenio (abemaciclib) label expansion
7 December 2023 - Verzenio's label expanded to include the full study population investigated in the Verzenio Phase 3 monarchE trial.
Eli Lilly Canada is pleased to announce that Health Canada has authorised the label expansion of Verzenio (abemaciclib) to include the full intention to treat population from the Phase 3 monarchE trial.
